Comparative study between biofeedback retraining and botulinum neurotoxin in the treatment of anismus patients

被引:50
|
作者
Farid, Mohamed
Monem, Hisham Abd El
Omar, Waleed
Nakeeb, Ayman El [1 ]
Fikry, Amir
Youssef, Tamer
Yousef, Mohamed
Ghazy, Hosam
Fouda, Elyamani
Metwally, Teto El
Khafagy, Wael
Ahmed, Sabry
Awady, Salih El
Morshed, Mosaad
Lithy, Ramadan El
机构
[1] Mansoura Univ Hosp, Dept Gen Surg, Dep 8, Mansoura, Egypt
关键词
Obstructed defecation; Chronic constipation; Puborectalis; Pelvic floor; OUTLET OBSTRUCTION CONSTIPATION; PELVIC FLOOR SYNDROME; TOXIN TYPE-A; PUBORECTALIS SYNDROME; THERAPY; EXPERIENCE;
D O I
10.1007/s00384-008-0567-0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Purpose Anismus is a significant cause of chronic constipation. This study came to revive the results of BFB training and BTX-A injection in the treatment of anismus patients. Materials and methods Forty-eight patients with anismus (33 women; mean age 39.6 +/- 15.9) were included in this study. All patients fulfilled Rome II criteria for functional constipation. All patients underwent anorectal manometry, balloon expulsion test, defecography, and electromyography (EMG) activity of the EAS. All patients had non-relaxing puborectalis muscle. The patients were randomized into two groups. Group I patients received biofeedback therapy, two times per week for about 1 month. Group II patients were injected with BTX-A. Follow-up was conducted weekly in the first month then monthly for about 1 year. Results In the BFB training group, three patients quit before the end of sessions with no improvement; initial improvement was recorded in 12 patients (50%) while long-term success was recorded in six patients (25%). In the BTX-A group, clinical improvement was recorded in 17 patients (70.83%), but the improvement persisted only in eight patients (33.3%). There is a significant difference between BTX-A group and BFB group regarding the initial success, but this significant difference disappeared at the end of follow-up. Manometric relaxation was achieved significantly post-BFB and post-BTX-A injection with no significant difference between the two groups. Conclusions Biofeedback training has a limited therapeutic effect on patients suffering from anismus. BTX-A injection seems to be successful for temporary treatment of anismus.
引用
收藏
页码:115 / 120
页数:6
相关论文
共 50 条
  • [21] Prospects and limitations of treatment with botulinum neurotoxin type A for patients with refractory idiopathic detrusor overactivity
    Schmid, D. M.
    Roy, S.
    Sulser, T.
    Scheiner, D.
    BJU INTERNATIONAL, 2008, 102 : 7 - 10
  • [22] Incidence of Dysphagia and Comorbidities in Patients with Cervical Dystonia, Analyzed by Botulinum Neurotoxin Treatment Exposure
    Barbano, Richard L.
    Jabbari, Bahman
    Sadeghi, Marjan
    Ukah, Ahunna
    Yue, Emma
    Ifantides, Kimberly Becker
    Huang, Nuo-Yu
    Swope, David
    TOXINS, 2025, 17 (03)
  • [23] DaxibotulinumtoxinA for Injection is similarly effective in experienced botulinum neurotoxin patients and in those naive to treatment
    Cohen, Joel L.
    Green, Lawrence J.
    Beer, Kenneth Robert
    Gallagher, Conor J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB96 - AB96
  • [24] Incidence of Dysphagia and Comorbidities in Patients with Cervical Dystonia, Analyzed by Botulinum Neurotoxin Treatment Exposure
    Sadeghi, M.
    Ukah, A.
    Yue, E.
    Ifantides, K. Becker
    Huang, N.
    Lee, J.
    Barbano, R.
    MOVEMENT DISORDERS, 2023, 38 : S351 - S352
  • [25] Multimodal physiotherapy as an add-on treatment to botulinum neurotoxin therapy in patients with cervical dystonia
    Werner, C.
    Derlien, S.
    Witte, O. W.
    Guenther, A.
    Smolenski, U. C.
    JOURNAL OF NEURAL TRANSMISSION, 2016, 123 (12) : 1524 - 1525
  • [26] Incidence of Dysphagia and Comorbidities in Patients With Cervical Dystonia, Analyzed by Botulinum Neurotoxin Treatment Exposure
    Sadeghi, Marjan
    Ukah, Ahunna
    Yue, Emma Xiaomeng
    Ifantides, Kim Becker
    Huang, Nuo-Yu
    Lee, Joan
    Barbano, Richard L.
    TOXICON, 2024, 237 : 75 - 77
  • [27] Safety and administration of treatment with botulinum neurotoxin for sialorrhoea in ALS patients: Review of the literature and a proposal for tailored treatment
    Stokholm, Morten Gersel
    Bisgard, Carsten
    Vilholm, Ole Jakob
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2013, 14 (7-8) : 516 - 520
  • [28] Botulinum neurotoxin treatment in children with cerebral palsy: A population-based study in Norway
    Elkamil, Areej I.
    Andersen, Guro L.
    Skranes, Jon
    Lamvik, Torarin
    Vik, Torstein
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2012, 16 (05) : 522 - 527
  • [29] AN INTERNATIONAL, NONINTERVENTIONAL STUDY OF BOTULINUM NEUROTOXIN TYPE A IN TREATMENT-NAIVE SUBJECTS WITH SPASTICITY
    Harriss, Julian
    Roche, Nicolas
    Cantu-Brito, Carlos
    Khatkova, Svetlana
    Satero, Patrik
    Heitmann, Susanne
    Simon, Olivier
    Kliebe-Frisch, Christine
    Sternberg, Kati
    Jost, Wolfgang H.
    TOXICON, 2018, 156 : S44 - S44
  • [30] An Open Study of Botulinum Neurotoxin Type A in the Treatment of Chronic Neuropathic Pain for One Year
    Laterza, Vincenzo
    Magro, Giuseppe
    Spano, Giorgio
    Idone, Giovanni
    Bono, Francesco
    TOXICON, 2024, 237 : 47 - 47